ClinicalTrials.gg
RecruitingNCT07671924LAKEUpdated Nov 5, 2026

The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

A Phase 2 interventional study of NAL ER and Placebo in Refractory Chronic Cough, sponsored by Trevi Therapeutics. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 5, 2026First site in United KingdomStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Chronic Cough with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Chronic Cough · Canada.

Planned enrollment
12th of 18
100 · median 122
Started
2026
with 1 other
Phase 2
7 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
2 of 22
Trevi Therapeutics

Among the 22 studies in Chronic Cough with a site in Canada, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 2, and was the 22nd registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

7 of the 22 studies in Chronic Cough with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Cough with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.

03

Conditions studied

  • Refractory Chronic Cough

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets society guideline-based criteria for a diagnosis of RCC defined as:

    • Insufficient improvement in cough after treatment for any identified cough-associated conditions.
    • Unexplained cough for which an underlying condition has not been determined despite adequate investigation with diagnostic tests and trials of therapy.
  • Persistent and chronic cough for at least one year prior to Screening.
  • Chest computed tomography (CT) or chest radiograph of the thorax performed within the last 24 months and after the onset of chronic cough OR the procedure completed by the Investigator during the Screening period, that does not show any abnormality considered to be significantly contributing to the RCC in the opinion of the Principal Investigator.
  • 24-hour objective cough frequency ≥10 coughs/hour based on VitaloJAK® cough monitor recording performed during the Screening and Placebo Run-in Periods as well as a minimum recording duration of 20 hours suitable for analysis during the placebo Run-in assessment.
  • (FEV1) /forced vital capacity (FVC) ratio ≥ 60% as determined by spirometry adhering to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of sleep apnea and/or use of continuous positive airway pressure (CPAP).
  • Upper or lower respiratory tract infection or change in pulmonary status in the 4 weeks prior to the Screening visit or during the Screening or PBO Run-in periods.
  • History of bronchiectasis, (COPD) or idiopathic pulmonary fibrosis (IPF), or other significant respiratory disorder that might affect cough.
  • History of uncontrolled asthma defined as one of the following:

    • ≥1 exacerbation in the last 6 months, OR
    • ≥2 clinically significant exacerbations in the past 12 months (a clinically significant asthma exacerbation is defined as requiring the use of systemic ).
  • Current smoker or vaper or current use of tobacco smoke, cannabis smoke, or nicotine vaper.
  • Individuals who have stopped smoking or vaping within the past 6 months, or those with >20 pack-year smoking history.
  • Current active tuberculosis or nontuberculous mycobacterial infection, a history of latent untreated tuberculosis, or a history of incompletely treated tuberculosis.
  • Speech therapy/physiotherapy for RCC starting within 4 weeks of Baseline or during the study. Speech therapy/physiotherapy is acceptable if the participant has started the therapy more than 4 weeks prior to the Baseline visit AND plans to continue the therapy through the Titration and Fixed-dose Treatment Period.
  • Known intolerance [gastrointestinal, central nervous system (CNS) symptoms], , or drug allergy considered to be related to an opioid drug or known hypersensitivity to nalbuphine or to NAL ER .

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    NAL ER 54 mg BID

    Participants will receive NAL ER during the titration period, with dose titration starting at 27 milligrams (mg) once daily (QD) and increasing up to 54 mg twice daily (BID) from Day 1 to Day 14. Participants will receive NAL ER 54 mg BID during the fixed-dose treatment period from Day 15 to Day 42.

    Drug: NAL ER · Drug: Placebo

  • Experimental
    NAL ER 27 mg BID

    Participants will receive NAL ER during the titration period, starting at 27 mg QD to 27 mg BID from Day 1 to Day 14. Participants will receive NAL ER 27 mg BID during the fixed-dose treatment period from Day 15 to Day 42.

    Drug: NAL ER · Drug: Placebo

  • Experimental
    NAL ER 27 mg QD

    Participants will receive NAL ER 27 mg QD during the titration period from Day 1 to Day 14. Participants will continue to receive NAL ER 27 mg QD during the fixed-dose treatment period from Day 15 to Day 42.

    Drug: NAL ER · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive matching placebo during the titration period from Day 1 to Day 14 and the fixed-dose treatment period from Day 15 to Day 42.

    Drug: Placebo

Interventions

  • DrugNAL ER

    Oral tablets

    Also known as: Nalbuphine

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in 24-hour Cough Frequency at Week 6

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Relative Change From Baseline in 24-hour Cough Frequency

    Time frame: Baseline up to Week 6

  2. Percentage of Participants Achieving ≥30%, ≥50% and ≥75% Reduction in 24-hour Cough Frequency

    Time frame: Baseline up to Week 6

  3. Change From Baseline in Patient Reported Cough Frequency (PR-CF)

    Time frame: Baseline up to Week 6

  4. Change From Baseline in Cough Severity Visual Analog Scale (CS-VAS)

    Time frame: Baseline up to Week 6

  5. Percentage of Participants Achieving a 30 Millimeter (mm) Improvement in CS-VAS Total Score

    Time frame: Baseline up to Week 6

  6. Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS)

    Time frame: Baseline up to Week 6

  7. Change From Baseline in McMaster Cough Severity Questionnaire (MCSQ) Total Score

    Time frame: Baseline up to Week 6

  8. Change From Baseline in MCSQ Domains (Intensity and Frequency)

    Time frame: Baseline up to Week 6

  9. Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6

    Time frame: Baseline, Week 6

  10. Change From Baseline in Each LCQ Domain Score (Physical, Psychological, Social) at Week 6

    Time frame: Baseline, Week 6

  11. Percentage of Participants Achieving a 1.3- Point Increase From Baseline in LCQ Total Score at Week 6

    Time frame: Baseline, Week 6

  12. Relative Change From Baseline in Awake Cough Frequency

    Time frame: Baseline up to Week 6

  13. Relative Change From Baseline in Sleep Cough Frequency

    Time frame: Baseline up to Week 6

  14. Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score

    Time frame: Baseline up to Week 6

  15. Mean Patient Global Impression of Change for Cough (PGI-C) Cough Score

    Time frame: Up to Week 6

  16. Change From Baseline in International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF) Score at Week 6

    Time frame: Baseline, Week 6

  17. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 63

07

Study locations

21 of 21 sites recruiting
  • Kelowna Respirology & Allergy Research
    Kelowna, British Columbia V1Y3H5, Canada
    Recruiting
  • Inspiration Research Limited
    Toronto, Ontario M5T3A9, Canada
    Recruiting
  • Dynamic Drug Advancement Ltd
    Ajax, L1S 2J5, Canada
    Recruiting
  • BLC Clinical Research
    Burlington, L7N3V2, Canada
    Recruiting
  • Recherche GCP Research
    Montreal, H1Y3H5, Canada
    Recruiting
  • Medical Arts Health Research Group - North Vancouver
    North Van Couver, V7P2T4, Canada
    Recruiting
  • Diex Recherche - Quebec
    Québec, G1V4T3, Canada
    Recruiting
  • Clinique Specialisee En Allergie De La Capitale
    Québec, G1V4W2, Canada
    Recruiting
  • Clinque DE Pneumologie ET Du Sommeil DE Lanaudiere
    Saint-Charles-Borromée, J6E 2B4, Canada
    Recruiting
  • Centre D'Investigation Clinique Mauricie Inc (CIC Mauricie)
    Trois-Rivières, G8T7A1, Canada
    Recruiting
  • Diex Recherche-Victoriaville
    Victoriaville, G6P3Z8, Canada
    Recruiting
  • Ormeau Clinical Trials LTD.
    Belfast, BT2 8BG, United Kingdom
    Recruiting
  • West Walk Surgery
    Bristol, BS37 4AX, United Kingdom
    Recruiting
  • Hull University Teaching Hospitals NHS Trust - Respiratory Clinical Trials Unit
    Cottingham, HU16 5JQ, United Kingdom
    Recruiting
  • Northwick Park Hospital
    Harrow, HA1 3UJ, United Kingdom
    Recruiting
  • NIHR Leicester Biomedical Research Centre Leicester General Hospital
    Leicester, LE3 9QP, United Kingdom
    Recruiting
  • King's College Hospital (KCH) NHS Foundation Trust - King's College Hospital
    London, SE5 9RS, United Kingdom
    Recruiting
  • Manchester University NHS Foundation Trust - Wythenshawe Hospital - North West Lung Centre
    Manchester, M23 9LT, United Kingdom
    Recruiting
  • Pier Health Group
    North Somerset, BS24 7PR, United Kingdom
    Recruiting
  • The Breckland Alliance - Grove Surgery
    Thetford, IP24 1JD, United Kingdom
    Recruiting
  • Northumbria Healthcare NHS Foundation Trust - North Tyneside General Hospital
    Tyne and Wear, NE29 8NH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 1 site removed — first site in United Kingdom
Show 12 added (10 United Kingdom, 2 Canada)
  • Inspiration Research Limited · Toronto, Canada
  • Kelowna Respirology & Allergy Research · Kelowna, Canada
  • Ormeau Clinical Trials LTD. · Belfast, United Kingdom
  • West Walk Surgery · Bristol, United Kingdom
  • Hull University Teaching Hospitals NHS Trust - Respiratory Clinical Trials Unit · Cottingham, United Kingdom
  • Northwick Park Hospital · Harrow, United Kingdom
  • NIHR Leicester Biomedical Research Centre Leicester General Hospital · Leicester, United Kingdom
  • King's College Hospital (KCH) NHS Foundation Trust - King's College Hospital · London, United Kingdom
  • Manchester University NHS Foundation Trust - Wythenshawe Hospital - North West Lung Centre · Manchester, United Kingdom
  • Pier Health Group · North Somerset, United Kingdom
  • The Breckland Alliance - Grove Surgery · Thetford, United Kingdom
  • Northumbria Healthcare NHS Foundation Trust - North Tyneside General Hospital · Tyne and Wear, United Kingdom
Show 1 removed
  • Fadia El Boreky Medicine Prof. Corp. · Waterloo, Canada
across 2 updates, Oct 13, 2026 – Nov 5, 2026
Contact
Study contact changed: removed (no phone or email listed). See the current contact
Oct 13, 2026
Show all 2 updates
  1. Nov 5, 2026
    11 sites added — first site in United Kingdom
    Show 11 added (10 United Kingdom, 1 Canada)
    • Kelowna Respirology & Allergy Research · Kelowna, Canada
    • Ormeau Clinical Trials LTD. · Belfast, United Kingdom
    • West Walk Surgery · Bristol, United Kingdom
    • Hull University Teaching Hospitals NHS Trust - Respiratory Clinical Trials Unit · Cottingham, United Kingdom
    • Northwick Park Hospital · Harrow, United Kingdom
    • NIHR Leicester Biomedical Research Centre Leicester General Hospital · Leicester, United Kingdom
    • King's College Hospital (KCH) NHS Foundation Trust - King's College Hospital · London, United Kingdom
    • Manchester University NHS Foundation Trust - Wythenshawe Hospital - North West Lung Centre · Manchester, United Kingdom
    • Pier Health Group · North Somerset, United Kingdom
    • The Breckland Alliance - Grove Surgery · Thetford, United Kingdom
    • Northumbria Healthcare NHS Foundation Trust - North Tyneside General Hospital · Tyne and Wear, United Kingdom
    + 1 other change: verification date
  2. Oct 13, 2026
    1 site added, 1 site removed
    Show site
    • Inspiration Research Limited · Toronto, Canada
    Show 1 removed
    • Fadia El Boreky Medicine Prof. Corp. · Waterloo, Canada
    Contact Study contact changed: removed (no phone or email listed). See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07671924
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jun 22, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Paula Buckley
Contact
Paula.Buckley@trevitherapeutics.com
(203) 304-2499
Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion